Natco Pharma
Natco Pharma Limited, headquartered in Hyderabad, India, is a prominent player in the pharmaceutical industry, specialising in the development, manufacturing, and marketing of generic and specialty medicines. Founded in 1981, the company has achieved significant milestones, including the launch of several high-quality generic formulations and active pharmaceutical ingredients (APIs) that cater to various therapeutic areas such as oncology, cardiology, and neurology.
With a strong presence in both domestic and international markets, Natco Pharma is recognised for its commitment to innovation and affordability. The company’s core products, including complex generics and biosimilars, stand out due to their quality and accessibility. Natco's strategic focus on research and development has positioned it as a leader in the pharmaceutical sector, earning accolades for its contributions to healthcare and patient well-being.
-8 vs industry average
Natco Pharma’s score of 30 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Natco Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Natco Pharma's reported carbon emissions
In 2025, Natco Pharma reported total carbon emissions of approximately 72,124,850 kg CO2e, comprising 28,494,500 kg CO2e from Scope 1 and 43,630,350 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming to enhance its renewable energy mix to 35% by 2035 and achieve carbon neutrality by 2050. These targets apply to all scopes of emissions, including Scope 1 and Scope 2, reflecting a long-term strategy for sustainability. In previous years, Natco Pharma's emissions were approximately 70,166,900 kg CO2e in 2024 and about 71,287,300 kg CO2e in 2023, indicating a consistent focus on managing and reducing their carbon footprint. However, data for Scope 3 emissions is currently unavailable, highlighting an area for potential improvement in their emissions reporting. Natco Pharma's commitment to renewable energy and carbon neutrality aligns with industry standards for climate action, demonstrating a proactive approach to environmental responsibility.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Natco Pharma’s Climate Goals (2030 & 2050)
3 goals2035
35% reduction in Scope 1
We aim to enhance RE in our energy mix up to 35% by the end of 2035.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 3 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Natco Pharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project